Aaron P. Rapoport
Hematology Oncology | Oncology
22 South Greene Street
Floor 1
Baltimore, MD 21201
Floor 1
Baltimore, MD 21201
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 111 publications
Predictors of Rehabilitation Utilization After CAR T-Cell Therapy.
Journal: Transplantation and cellular therapy
Published: April 29, 2026
Implementation of a Multidisciplinary Eye Clinic within a Cancer Center for Patients at Risk of Ocular Graft versus Host Disease.
Journal: Ophthalmology science
Published: February 10, 2026
Beyond the typical immune effector cell-associated neurotoxicity syndrome: Characterizing non-immune effector cell-associated neurotoxicity syndrome neurological complications in chimeric antigen receptor T-cell therapy-A retrospective analysis.
Journal: Neuro-oncology advances
Published: February 09, 2026
Would you, could you drive CARs to point-of-care manufacturing? Yes, you should!
Journal: Haematologica
Published: January 14, 2026
Real-World Experience With a ZUMA-1 Cohort 4 Adopted Approach to CRS and ICANS in CAR-T Recipients.
Journal: European journal of haematology
Published: October 20, 2025
Faecal microbiota transplant for chronic norovirus infection: a case report of donor microbiota engraftment without clinical success.
Journal: Gastroenterology report
Published: August 23, 2025
CNS infiltration by zamtocabtagene autoleucel tandem CD20/CD19 CAR T cells leading to complete remission in a patient with primary CNS lymphoma.
Journal: Haematologica
Published: August 01, 2025
Lisocabtagene maraleucel in patients with relapsed or refractory marginal zone lymphoma (TRANSCEND FL): primary analysis results from the global, multicohort, single-arm, phase 2 study.
Journal: Lancet (London, England)
Published: July 15, 2025
Comprehensive Assessment of CD19 Immunohistochemical Staining in Classic Hodgkin Lymphoma.
Journal: The American journal of surgical pathology
Published: June 28, 2025
Obecabtagene autoleucel, a novel CD19-directed CAR T-cell therapy for relapsed/refractory B-cell acute lymphoblastic leukemia: the future for reducing toxicity and T-cell exhaustion?
Journal: Expert review of hematology
Published: June 23, 2025
Outpatient axicabtagene ciloleucel for relapsed/refractory large B-cell lymphoma: ZUMA-24 primary analysis.
Journal: American journal of cancer research
Published: May 19, 2025
Last Updated: 09/26/2026